Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry

cafead

Administrator
Staff member
  • cafead   Mar 19, 2024 at 12:12: PM
via Engrail Therapeutics has closed a nine-digit series B to further its neuropsychiatric pipeline, the latest evidence that investors are flocking to fund new treatments in this resurgent therapeutic area.

article source
 

<